C Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner, Biokin Pharmaceutical, on receiving implied approval from the...

On August 22, 2025, Mednovo Medical Technology Group Co., Ltd. (“Mednovo”) successfully administered the first patient in the Phase III clinical trial of its Class III radiotherapeutic, Lutetium [Lu-177] Oxodotreotide Injection.

C Ray Therapeutics (Chengdu, China), a global radiopharmaceutical CRDMO, today announced the execution of a Master Radioisotope Supply Agreement with SHINE Technologies, LLC (Janesville, Wisconsin, USA), establishing a long-term, GMP-compliant supply of no-carrier-added lutetium-177 (n.c.a. Lu-177) and granting C-Ray exclusive distribution rights for this critical medical isotope across mainland China — excluding certain pre-existing SHINE partnerships.

Welcoming the New Year with a Major MilestoneTongrui Biopharmaceuticals Earns AAALAC Full Accreditation Embarking on a New Chapter of High-Quality Development

As one year gives way to the next, a new chapter unfolds.

The J.P. Morgan Healthcare Conference will be held from January 12 to 15, 2026.

On the fast track of radiopharmaceutical R&D and production, C Ray remains steadfastly client-centric, continuously strengthening its infrastructure and radionuclide capabilities.